在当前医疗领域中，心血管疾病（CVD）、慢性肾脏疾病（CKD）与糖尿病（T2DM）之间的病理生理关系已成为医学研究的重要课题，受到广泛的关注和重视。CVD、CKD和T2DM存在多种交叉的病理生理机制，互为因果，常合并存在，且彼此加重不良预后。这些疾病的高度共病率使得综合管理尤为重要。在第十八届东方心脏病学会议暨世界心脏 ...

前言慢性肾脏疾病（CKD）是一个全球性的健康问题。由于人口老龄化的增加以及肥胖、2型糖尿病（T2DM）、高血压、心血管疾病（CVD）的流行，CKD患病率正在迅速增长[1]。随着研究的不断深入以及诊疗理念的不断革新，“心-肾-代谢（CKM）综合征”这一概念应运而生，强调了三大疾病（CVD、CKD和T2DM）之间的密切关系和相互作用[ ...

它不仅会引发肾脏功能的逐渐衰退，还与心血管疾病（Cardiovascular Disease，CVD）等多种严重并发症紧密相连。在不同地区，CKD 患者的疾病发展和临床结局存在显著差异。西方 CKD 患者中，CVD 是导致死亡的主要原因；而韩国 CKD 患者却有着独特的表现，其 CVD 发病率 ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Given the well-established link between CKD and an increased risk of CVD, KDIGO reinforces its recommendation for statin therapy in adults with CKD, particularly those aged 50 years and older.

Globally, the rate of death from chronic kidney disease increased 24% from 1990 to 2021, according to statistics published by ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...